Ranibizumab:

Ranibizumab is a monoclonal antibody fragment derived medication used in the treatment of a variety of eye-related ailments. Originally developed by the biotech manufacturer Genetech in the United States, it was first approved for the treatment of wet age-related macular degeneration by the FDA in 2006 and later subsequently approved for the treatment of both diabetic macular and edema macular edema following retinal vein occlusion. In addition, it was further approved in 2015 for diabetic retinopathy treatment in patients. Currently, ranibizumab manufacturers and ranibizumab suppliers list it both for sale and wholesale across the global marketplace, where it is frequently bought by distributors and can regularly be found under trade names such as Lucentis.

Method of action of ranibizumab:

Ranibizumab belongs to a class of drugs termed vascular endothelial growth factor A (VEGF-A) antagonists. This group of pharmaceutical products are named due to their inhibitory effect on human VEGF-A. This effect is specifically conferred to ranibizumab by its composition consisting of recombinant humanized IgG1 kappa isotype monoclonal antibody fragments. Thus it is capable of binding to both VEGF-A and its biologically active cleaved form, preventing VEGF-A from interacting with its receptors VEGFR1 and VEGFR2 on the surface of endothelial cells. Therefore as VEGF-A is inhibited and its subsequent pathway is downregulated, neovascularization and angiogenesis are reduced. Leading to an abatement of endothelial cell proliferation, vascular leakage, and new blood vessel formation. Which are all thought to be contributing factors to ocular illnesses such as age-related macular degeneration (AMD).

Ranibizumab form and dosage:

Ranibizumab manufacturers, suppliers, and distributors predominantly list it for sale in forms consisting of pre-filled syringes and vials. As it is a prescribed product, authorization from a specialist medical professional is necessary for use, which is administered by way of an intravitreal injection to the back of the eye. Initial dose and frequency are typically 500 mg once a month, continuing until maximum visual acuity or until cessation of disease activity. This however is subject to medical discretion, as procedures such as laser photocoagulation in response to certain illnesses recommend the administration of 500 mg of ranibizumab 30 minutes post-operation.

Ranibizumab on Pipelinepharma:

A variety of pharmaceutical products such as ranibizumab are available to order B2B on our online company Pipelinepharma.com website. This offers an effective method of sourcing both global ranibizumab manufacturers and wholesale ranibizumab suppliers in an accessible and cost-effective manner. A search currently reveals one listing for ranibizumab from a manufacturer located in the European Union, with purchase price provided upon request.

Price of ranibizumab and how to buy:

Identically to other products and provided it is not otherwise stated, the cost of purchase will be dynamically negotiable online between both B2B parties. To initiate a purchase inquiry, search for the desired pharmaceutical product through the online Pipelinepharma marketplace, select the desired listing, and then navigate to the orange inquiry button on the right labelled either ‘Get offer’, ‘Accept’, or ‘Negotiate’, depending on the specific listing. This online search and purchase method serves to expedite agreements and enable rapid transactions to take place between both the buyer and Pipelinepharma verified manufacturers and distributors.